Cargando…

Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC

Recent sequencing studies of clear cell (conventional) renal cell carcinoma (ccRCC) have identified inactivating point mutations in the chromatin-modifying genes PBRM1, KDM6A/UTX, KDM5C/JARID1C, SETD2, MLL2 and BAP1. To investigate whether aberrant hypermethylation is a mechanism of inactivation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibragimova, Ilsiya, Maradeo, Marie E., Dulaimi, Essel, Cairns, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741218/ https://www.ncbi.nlm.nih.gov/pubmed/23644518 http://dx.doi.org/10.4161/epi.24552

Ejemplares similares

Genome-Wide Promoter Methylome of Small Renal Masses
por: Ibragimova, Ilsiya, et al.
Publicado: (2013)

Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma()
por: Bihr, Svenja, et al.
Publicado: (2019)

Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma
por: Piva, Francesco, et al.
Publicado: (2015)

Functional role of SETD2, BAP1, PARP-3 and PBRM1 candidate genes on the regulation of hTERT gene expression
por: Linne, Hannah, et al.
Publicado: (2017)

A global profile of gene promoter methylation in treatment-naïve urothelial cancer
por: Ibragimova, Ilsiya, et al.
Publicado: (2014)

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor
por: Eckel-Passow, Jeanette E., et al.
Publicado: (2017)

Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA
por: Kluzek, Katarzyna, et al.
Publicado: (2017)

An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC)
por: Wang, Yuanyuan, et al.
Publicado: (2016)

Erratum to: An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC)
por: Wang, Yuanyuan, et al.
Publicado: (2016)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth
por: Cai, Weijia, et al.
Publicado: (2019)

Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC
por: Xue, Wei, et al.
Publicado: (2023)

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
por: Carril-Ajuria, Lucía, et al.
Publicado: (2019)

Data supporting the roles of BAP1, STING, and IFN-β in ISGF3 activation in ccRCC
por: Langbein, Lauren E., et al.
Publicado: (2022)

PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma
por: Chowdhury, Basudev, et al.
Publicado: (2016)

Development and validation of a PBRM1‐associated immune prognostic model for clear cell renal cell carcinoma
por: Chen, Jiayi, et al.
Publicado: (2021)

Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma
por: Murakami, A, et al.
Publicado: (2017)

PBRM1 Regulates Stress Response in Epithelial Cells
por: Porter, Elizabeth G., et al.
Publicado: (2019)

Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X
por: Joseph, Nancy M., et al.
Publicado: (2016)

Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway
por: Gad, Sophie, et al.
Publicado: (2021)

PBRM1 bromodomains associate with RNA to facilitate chromatin association
por: De Silva, Saumya M, et al.
Publicado: (2023)

Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
por: Doppalapudi, Sai Krishnaraya, et al.
Publicado: (2021)

Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression
por: Karlsson, Jenny, et al.
Publicado: (2016)

PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma
por: Saiga, Kazuho, et al.
Publicado: (2022)

Relationship between body composition and PBRM1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis
por: Demirel, Emin, et al.
Publicado: (2023)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1
por: Ge, Yu-Zheng, et al.
Publicado: (2017)

Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review
por: Lian, Bi-Jun, et al.
Publicado: (2022)

Role of the Pbrm1 subunit and the PBAF complex in Schwann cell development
por: Polanetzki, Vanessa, et al.
Publicado: (2022)

A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors
por: Liu, Jin, et al.
Publicado: (2022)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
por: Dai, Jiali, et al.
Publicado: (2023)

Comments on “Relationship between body composition and PBRM1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis”
por: Pontes-Silva, André, et al.
Publicado: (2023)

Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)
por: Rysz, Jacek, et al.
Publicado: (2021)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma
por: Cheng, Huan, et al.
Publicado: (2012)

PBRM1 deficiency oncogenic addiction is associated with activated AKT–mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells
por: Tang, Yu, et al.
Publicado: (2022)

BAP1 Tumour Predisposition Syndrome Due to Whole BAP1 Gene Deletion
por: Pandithan, Dinusha, et al.
Publicado: (2022)

BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
por: Blatnik, Ana, et al.
Publicado: (2022)

Pbrm1 intrinsically controls the development and effector differentiation of iNKT cells
por: Wang, Xin, et al.
Publicado: (2022)

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma
por: Yu, Mengxue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d7sbos71koetp18217bucrtlrh